Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

BACKGROUND: Several anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) therapies have shown encouraging safety and clinical activity in a variety of tumor types. A potential role for PD-L1 testing in identifying patients that are more likely to respond to treatment i...

Descripción completa

Detalles Bibliográficos
Autores principales: Scorer, Paul, Scott, Marietta, Lawson, Nicola, Ratcliffe, Marianne J., Barker, Craig, Rebelatto, Marlon C., Walker, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058354/
https://www.ncbi.nlm.nih.gov/pubmed/30041679
http://dx.doi.org/10.1186/s13000-018-0725-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058354/
https://www.ncbi.nlm.nih.gov/pubmed/30041679
http://dx.doi.org/10.1186/s13000-018-0725-9

Ejemplares similares